What Next for Fluidigm Corporation (FLDM) Stock After Reaching 52-Week High?

February 19, 2018 - By Rodney Autry

Investors sentiment increased to 1.58 in Q3 2017. Its up 0.37, from 1.21 in 2017Q2. It improved, as 7 investors sold Fluidigm Corporation shares while 17 reduced holdings. 8 funds opened positions while 30 raised stakes. 32.41 million shares or 37.16% more from 23.63 million shares in 2017Q2 were reported.
Fifth Third Savings Bank holds 0% or 516 shares. Panagora Asset Incorporated invested in 391,374 shares. State Board Of Administration Of Florida Retirement System holds 27,408 shares. Jacobs Levy Equity accumulated 0.02% or 238,101 shares. D E Shaw Com holds 151,651 shares or 0% of its portfolio. Price T Rowe Associate Inc Md owns 14,900 shares for 0% of their portfolio. Moreover, Fic Cap has 0.36% invested in Fluidigm Corporation (NASDAQ:FLDM). Acadian Asset Management Lc reported 0% in Fluidigm Corporation (NASDAQ:FLDM). Moreover, Rhumbline Advisers has 0% invested in Fluidigm Corporation (NASDAQ:FLDM). Credit Suisse Ag invested in 0% or 20,051 shares. Parametric Assoc Limited Liability holds 0% or 37,974 shares. Geode Capital Limited Company accumulated 0% or 230,850 shares. Tower Rech Cap Ltd Liability Corporation (Trc) holds 0% or 11,639 shares. Prelude Capital Mngmt Ltd Com holds 0% or 5,595 shares. Connor Clark Lunn Invest Management has invested 0% in Fluidigm Corporation (NASDAQ:FLDM).

Since October 16, 2017, it had 14 buys, and 0 sales for $3.65 million activity.

The stock of Fluidigm Corporation (NASDAQ:FLDM) hit a new 52-week high and has $8.23 target or 6.00 % above today’s $7.76 share price. The 5 months bullish chart indicates low risk for the $299.91M company. The 1-year high was reported on Feb, 19 by Barchart.com. If the $8.23 price target is reached, the company will be worth $17.99M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock decreased 2.63% or $0.21 during the last trading session, reaching $7.76. About 331,349 shares traded or 55.49% up from the average. Fluidigm Corporation (NASDAQ:FLDM) has declined 36.51% since February 19, 2017 and is downtrending. It has underperformed by 53.21% the S&P500.

Fluidigm Corporation (NASDAQ:FLDM) Ratings Coverage

Among 5 analysts covering Fluidigm (NASDAQ:FLDM), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Fluidigm had 22 analyst reports since August 7, 2015 according to SRatingsIntel. The stock of Fluidigm Corporation (NASDAQ:FLDM) earned “Hold” rating by Maxim Group on Thursday, August 27. The firm has “Hold” rating by Piper Jaffray given on Thursday, February 8. The stock of Fluidigm Corporation (NASDAQ:FLDM) earned “Neutral” rating by Piper Jaffray on Friday, August 7. The company was maintained on Friday, August 7 by Mizuho. As per Friday, August 21, the company rating was upgraded by Zacks. The firm earned “Hold” rating on Friday, August 4 by Cowen & Co. Cantor Fitzgerald initiated the stock with “Hold” rating in Wednesday, August 26 report. The rating was maintained by Cantor Fitzgerald on Friday, August 5 with “Buy”. Deutsche Bank initiated Fluidigm Corporation (NASDAQ:FLDM) on Thursday, January 7 with “Buy” rating. The company was upgraded on Friday, February 5 by Mizuho.

More recent Fluidigm Corporation (NASDAQ:FLDM) news were published by: Globenewswire.com which released: “Fluidigm to Participate in Upcoming Health Care Investor Conferences” on February 14, 2018. Also Seekingalpha.com published the news titled: “Fluidigm Corp’s (FLDM) CEO Chris Linthwaite on Q4 2017 Results – Earnings Call …” on February 09, 2018. Globenewswire.com‘s news article titled: “Fluidigm to Report Q4 and Full Year 2017 Financial Results” with publication date: January 25, 2018 was also an interesting one.

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research. The company has market cap of $299.91 million. It offers preparatory instruments, such as access array system, juno system, and callisto system; analytical instruments comprising biomark HD and EP1 systems; integrated fluidic circuits consisting of access array, juno genotyping, dynamic array, digital array, flex six, and callisto IFCs; and assays and reagents, including delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. It currently has negative earnings. The firm also provides C1 single-cell systems, polaris systems, C1 IFCs, polaris IFCs, helios/CyTOF 2 systems, maxpar reagents, imaging mass cytometer instruments and reagents, and laser ablation modules.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.